**Core Concept**
The underlying principle being tested involves the management of smoking cessation in patients with comorbidities such as major depressive disorder and ischaemic heart disease. **Nicotinic acetylcholine receptors** and **dopamine** pathways play a crucial role in smoking addiction.

**Why the Correct Answer is Right**
Given the patient's history of major depressive disorder, a medication that can help with both smoking cessation and has a favorable profile for patients with depression is ideal. **Bupropion** is an antidepressant that also aids in smoking cessation by inhibiting the reuptake of **dopamine** and **norepinephrine**, thus reducing cravings and the withdrawal symptoms associated with quitting smoking.

**Why Each Wrong Option is Incorrect**
**Option A:** Incorrect because it is not specified, but typically, medications like **varenicline** are considered for smoking cessation. However, without knowing the exact option, it's hard to comment.
**Option C:** Incorrect as it might be related to **nicotine replacement therapy (NRT)**, which can be used but might not be the best option given the patient's depression.
**Option D:** Incorrect because, like Option A, it's unspecified, but could potentially be a medication not typically used as a first-line treatment for smoking cessation in patients with depression.

**Clinical Pearl / High-Yield Fact**
A key point to remember is that **bupropion** can be used for both depression and smoking cessation, making it a valuable option for patients with comorbid major depressive disorder.

**Correct Answer:** D. Bupropion.